All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
What are the key additions to the new NCCN guidelines for multiple myeloma?
Bookmark this article
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of Wisconsin-Madison, Madison, US and Shaji K. Kumar, Mayo Clinic, Rochester, US. We asked, What are the key additions to the new NCCN guidelines for multiple myeloma?
What are the key additions to the new NCCN guidelines for multiple myeloma?
Callander and Kumar discuss the inclusion of new diagnostic tools, such as MRD testing, risk-stratification for MM and it’s precursor stages, and changes to treatment regimens for newly diagnosed and relapsed MM. Callander also describes an important update for the recommendation of the combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone for the treatment of amyloidosis, providing supporting data from the phase III ANDROMEDA trial. They finish by discussing risk stratification and treatment intervention updates for smoldering MM.
Your opinion matters
59 votes - 53 days left ...
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox